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ABSTRACT
Seven triterpenoid saponins were identified in methanolic extracts of seeds of the Zolfino bean landrace
(Phaseolus vulgaris L.) by HPLC fractionation, revealing their ability to inhibit highly purified human recom-
binant aldose reductase (hAKR1B1). Six of these compounds were associated by MS analysis with the fol-
lowing saponins already reported in different Phaseolus vulgaris varieties: soyasaponin Ba (V), soyasaponin
Bb, soyasaponin Bd (sandosaponin A), soyasaponin ag, 3-O-[R-L-rhamnopyranosyl(1 ! 2)-a-D-glucopyrano-
syl(1 ! 2)-a-D-glucuronopyranosyl]olean-12-en-22-oxo-3a,-24-diol, and soyasaponin bg. The inhibitory
activity of the collected fractions containing the above compounds was tested for hAKR1B1-depend-
ent reduction of both L-idose and 4-hydroxynonenal, revealing that some are able to differentially
inhibit the enzyme. The present work also highlights the difficulties in the search for aldose reductase
differential inhibitors (ARDIs) in mixtures due to the masking effect on ARDIs exerted by the presence
of conventional aldose reductase inhibitors. The possibility of differential inhibition generated by a
different inhibitory model of action of molecules on different substrates undergoing transformation is
also discussed.
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Introduction
Saponins represent a wide family of compounds characterised by
the presence of either a triterpenoid or a steroidal aglycone moi-
ety and of one or more linked straight or branched sugar chains1.
Saponins are widely distributed in higher plants, and both the
aglycone and the saccharidic moieties of these molecules often
define their natural origin and, to some extent, their functional
properties and their industrial application2,3.
The amphiphilic nature of saponins provides these compounds
with a significant biological action by enabling them to interact at
the membrane level of the cell systems. In fact, they have been
reported to act as anti-inflammatory, hypocholesterolemic, expector-
ant, vasoprotective, and immunomodulating agents4,5. Nonetheless,
attention must be paid to the adverse cytotoxic action of saponins6,7.
Indeed, this feature of saponins has been widely investigated as a
potential tool to act against cell proliferation in cancer8.
As a result of their antioxidant and antidiabetic action, one of
the emerging features of saponins is their ability to inhibit aldose
reductase (AKR1B1). This enzyme (EC 1.1.1.21) catalyses the
NADPH-dependent reduction of a wide range of hydrophilic as
well as hydrophobic aldehydes. For several decades it has been
investigated in order to find molecules able to inhibit its reducing
activity on aldoses.
The rationale behind these investigations is based on the
apparent link, in hyperglycaemic conditions, between sorbitol
over-production and reducing power failure due to the AKR1B1
action and the development in diabetic subjects of pathological
states such as retinopathy, nephropathy, peripheral neuropathy,
cardiac dysfunctions, and cataracts9. Evidence of the effectiveness
of yuchasaponins from the flower buds of Camellia oleifera as
aldose reductase inhibitors (ARIs) on the rat lens enzyme has
been reported10. More recently, in vitro inhibition of aldose reduc-
tase in a crude liver homogenate and in vivo inhibition of the
enzyme in streptozotocin-induced diabetic rats, were reported for
a furostanol saponin and its derivatives, extracted from Balanites
aegyptiaca11,12. A triterpenoid oleanane saponin has also been
reported to interfere with the polyol pathway through aldose
reductase inhibition both in vivo in diabetic rats, and in an in vitro
model of diabetic peripheral neuropathy13.
Although such reports in the literature highlight the ability of
saponins to inhibit AKR1B1, to our knowledge no detailed kinetic
study on these molecules has been carried out, and no evidence
for their ability to act as aldose reductase differential inhibitors
(ARDIs) has been reported.
Differential inhibition concerns the ability of a molecule to exert
its inhibitory action depending on the nature of the substrate the
enzyme is working on14. Thus, the ability to preferentially inhibit the
reduction of sugar molecules with respect to hydrophobic aldehyde
reduction makes ARDIs promising tools to counteract the develop-
ment of secondary diabetic complications15,16.
In this work seven triterpenoid saponins were identified in
methanolic extracts of seeds of the Zolfino bean landrace
(Phaseolus vulgaris L.) revealing their ability to inhibit highly puri-
fied human recombinant hAKR1B1 and, for some of them, to dif-
ferentially inhibit the enzyme depending on the substrate (L-idose
or 4-hydroxynonenal, HNE) undergoing reduction.
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Materials and methods
Materials
Bovine serum albumin (BSA), D,L-dithiothreitol (DTT), D,L-glyceralde-
hyde (GAL), EDTA and DSC18 hydrophobic interaction cartridges
Supelco Discovery were purchased from Sigma-Aldrich (Saint Louis,
MO, USA). NADPH, L-idose, soyasaponin Ba (SSBa) and soyasaponin
Bb (SSBb) were supplied by Carbosynth (Compton, England); YM10
ultrafiltration membranes were obtained from Merck-Millipore
(Darmstad, Germany); soyasaponin Bd (SSBd) was obtained from ALB
Technology Limited (Mongkok Kowloon, Hong Kong); PTFE filtration
membranes 0.45mm pore size were from Phenomenex Italy (Bologna,
Italy); HPLC grade methanol, formic acid, and acetic acid were pur-
chased from VWR (Milano, Italy). HPLC grade water (18 MX) was pre-
pared by a Mill-X purification system (Millipore Corp., Bedford, MA).
All other chemicals were of reagent grade.
Dry seeds of yellow Zolfino landrace were obtained from the
farm Agostinelli Mario in Leccio-Reggello (Florence, Italy; 43 42’
N, 11 27’ E) and authenticity was confirmed by comparing their
features with those registered in the “Regione Toscana” germ-
plasm data bank (access VE_027): http://germoplasma.arsia.
toscana.it/.
Preparation of crude extracts from bean seeds
Dried bean seeds, mechanically disrupted by Ultra-Turrax, were
subjected to extraction by the addition (5ml/g) of 80% methanol
aqueous solution containing 0.6% (v/v) of acetic acid. The suspen-
sion was stirred for approximately 5 h at 4 C temperature in dark-
ness, centrifuged for 10min at 4 C at 7000 g, and the pellet
extracted again at 4 C overnight as above. All the solvents used
in the subsequent manipulation of the extract (water or methanol
solutions in water) contained 0.6% (v/v) final concentration of
acetic acid. The supernatants of the two centrifugation steps were
pooled, dried at room temperature by rotary evaporator, resus-
pended (2ml/g equivalents of the initial dry seeds) in 10%
Figure 1. Chromatographic fractionation of the hydrophobic components-enriched Zolfino bean extract. Panel A: the separation profile monitored at 254 nm of the
enriched extract applied (0.5ml) on the C18 column and eluted by a methanol-aqueous acetic acid gradient as indicated in the figure by a dotted line (see Materials
and Methods for details). Panel B: the percentage of inhibition exerted by the collected individual fractions (2ml) on the L-idose (black bars) and HNE (gray bars)
reduction. Eight mU of hAKR1B1 were used in the assay with 0.8mM and 0.04mM of L-idose and HNE, respectively, as substrates (see Materials and Methods for
details). Panel B (inset): the inhibitory action in the above assay conditions (% inhibition) exerted by different amounts of HPLC fraction F13 (AU254nm/mL assay) on the
hAKR1B1 catalysed reduction of L-idose (circles) and HNE (triangles) used as substrates. Error bars (when not visible are within the symbol size) represent the standard
deviations of the mean from at least three independent measurements. The statistical significance of differential inhibition % on L-idose reduction with respect to HNE
reduction is reported as: p< 0.0001 and p< 0.05.
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methanol aqueous solution and filtered through 0.45 mm PTFE
membrane filters.
Preparation and fractionation of “Zolfino bean-
enriched extract”
On the basis of previous results of the fractionation of Zolfino
extract on a reverse phase HPLC column through a methanol/
aqueous acetic acid gradient16, the extract was enriched in those
components with the highest hydrophobicity.
Thus, the extract was applied on 5ml DSC18 hydrophobic
interaction cartridges (1ml sorbent bed) previously conditioned
by sequential addition of 5ml of the following solutions (each
containing 0.6% acetic acid v/v): 100% methanol, water and 10%
methanol. A volume of 2.5ml of bean extract was applied to the
cartridge, and a stepwise elution was performed by the sequential
addition of 5ml of the following solutions: water, 10%, 30%, 50%,
and 100% methanol. The fraction eluting with 100% methanol
was concentrated by a rotary evaporator, diluted with water (con-
taining 0.6% acetic acid) to obtain 40% methanol in a final vol-
ume of 500 ll, and filtered through a 0.45mm PTFE membrane.
The sample obtained is referred to hereafter as the
“enriched extract”.
The “enriched extract” was fractionated by a SpectraSystem
HPLC instrument (Thermo, Rodano, Italy), equipped with a Kinetex
C18 column, 250 4.6mm ID, 5 mm particle size (Phenomenex,
Bologna, Italy). A mixture of methanol with 0.6% acetic acid (solv-
ent A) and a 0.6% v/v aqueous solution of acetic acid (solvent B)
were used as the eluent. The gradient profile was as follows:
0–6min, 40% A, isocratic mode; 6–26min, 40–100% A; 26–36min,
100% A, isocratic mode. Elution was performed at a flow rate of
1ml/min; the absorbance at 254 nm was monitored online. The
column was loaded with samples of about 1 g equivalent of the
initial dry seed weight per run. The eluate was collected by split-
ting it into 18 fractions, 2ml each.
Individual fractions (F1–18) were dried and resuspended in
0.1ml methanol and assayed (15ml) for hAKR1B1 inhibition ability.
Figure 2. Chromatographic fractionation of F13. The column eluate with tR from 24–26min (Figure 1, F13) from three different runs was pooled, dried, resuspended in
0.5ml of 55% methanol in 0.6% v/v aqueous solution of acetic acid and subjected to chromatographic separation in the conditions described in the Materials and
Methods. Panel A: reports the elution profile at 254 nm and the manually collected eluting fractions (namely 13 a–13 e). Panel B: the inhibitory ability of the collected
fractions on the hAKR1B1 catalysed reduction of L-idose (black bars) and HNE (gray bars). Error bars (when not visible are within the symbol size) represent the stand-
ard deviations of the mean from at least three independent measurements. The statistical significance of differential inhibition % on L-idose reduction with respect to
HNE reduction is reported as: p< 0.05.
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Aliquots of the HPLC fraction eluted with a retention time (tR)
from 24 to 26min (F13) were dried, resuspended in 55% methanol
with 0.6% acetic acid, and filtered through 0.45 mm PTFE mem-
brane. They were further purified by HPLC in the same conditions
described above, except for the elution programme, which was as
follows: 0–4min, 55% A, isocratic mode; 4–34min, 55–100% A;
34–44min, 100% A, isocratic mode. The solvent eluting from the
column between 22 and 28min was split into fractions, which
were named F13a, F13b and so on, and assayed for hAKR1B1
inhibition ability. In order to optimise the purification of the puta-
tive compounds with differential inhibition activity, the number of
fractions collected and the pattern of separation was fine-tuned
on the basis of the results of the bioassay. This led to the isolation
of five fractions (F13a–F13e), which were collected according to
their chromatographic profile thereby obtaining sub-frac-
tions F13a–e.
HPLC-PDA/UV-ESI-MS/MS analyses
HPLC-photodiode array (PDA)/UV-electrospray ionisation (ESI)-tan-
dem mass spectrometry (MS/MS) analyses were performed using a
Surveyor LC pump, a Surveyor autosampler, coupled with a
Surveyor PDA detector, and an LCQ Advantage ion trap mass
spectrometer (Thermo/Finnigan, San Jose, CA, USA) equipped with
Xcalibur 3.1 software. Analyses were performed on a
4.6 150mm, 4 mm, Synergi Fusion-RP column (Phenomenex Italy,
Bologna, Italy), using a mixture of methanol (solvent A) and a
0.05% v/v aqueous solution of formic acid (solvent B) as
the eluent.
The gradient profile was as follows: 0–6min, 40% A, isocratic
mode; 6–28min, 40–100% A; 28–36min 100% A, isocratic mode.
Elution was performed at a flow rate of 0.8ml/min with a splitting
system of 2:8 to the MS detector (160 ll/min) and the PDA
detector (640 ll/min), respectively. MS/MS analyses were per-
formed with an ESI interface in positive ion mode with a scan
range of m/z 150–2000, using N2 as the sheath and auxiliary gas.
The parameters used for MS operating conditions were opti-
mised as follows: capillary temperature, 270 C; sheath gas flow
rate, 60.00 arbitrary units; auxiliary gas flow rate, 3.00 arbitrary
units; capillary voltage, 32.00 V; tube lens offset, 10.00 V; spray
voltage, 4.50 kV. PDA data were recorded with a 200–600 nm
range. Analysed fractions 13a–e were first dried using a Speedvac
concentrator, then dissolved in methanol at a final concentration
of 2.0mg/ml and centrifuged; a volume of 20ll of supernatants
was injected into the LC-MS system.
Assay of aldose reductase
The AKR1B1 activity was determined at 37 C as previously
described17, monitoring the decrease in absorbance at 340 nm
linked to NADPH oxidation (e340¼6.22mM1 cm1) through a
Biochrom Libra S60 spectrophotometer. In a 0.25M sodium phos-
phate buffer pH 6.8, the standard assay mixture contained
0.18mM NADPH, 0.4M ammonium sulphate, 0.5mM EDTA and
4.7mM GAL. One unit of enzyme activity is the amount that catal-
yses the conversion of 1 mmol of substrate/min in the above assay
conditions. These assay conditions were also adopted to assess
the effectiveness of inhibitors when L-idose or HNE were used, at
the indicated concentrations, as substrates instead of GAL.
Differential inhibition (DI) refers to the difference between the
percentage inhibition observed using L-idose and HNE as sub-
strates in the assay conditions indicated.
Purification of human recombinant AKR1B1
The human recombinant AKR1B1 (hAKR1B1) was expressed and
purified to electrophoretic homogeneity as previously described18.
The purified enzyme (specific activity 5.3 U/mg) was stored at
80 C in a 10mM sodium phosphate buffer pH 7.0 containing
Figure 3. Extracted ion chromatograms of saponins 1–7 detected in fractions
13 a–e by LC-ESI-MS/MS analysis, registered in positive ion mode.
1¼ Soyasaponin Ba; 2¼ Soyasaponin Bb; 3¼Unidentified; 4¼ Soyasaponin Bd;
5¼ Soyasaponin ag; 6¼ 3-O-[R-L-rhamnopyranosyl(1 ! 2)-a-D-glucopyranosyl(1
! 2)-a-D-glucuronopyranosyl]olean-12-en-22-oxo-3a,-24-diol; 7¼ Soyasaponin bg.
Peak data are listed in Table 1. The structures of identified compounds are shown
in Figure 4.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 353
Figure 4. Structures of saponins 1, 2, and 4–7 detected in sub-fractions 13 a–e. The compound distribution into the fractions is shown in Figure 3.
Figure 5. ESI-MS/MS spectra of precursor ions [MþNa]þ of saponins 1 (Panel A) and 6 (Panel B), differing in the aglycone and in the saccharide portion. Gal: galact-
ose; Glc: glucose; Glu: glucuronic acid; Rha: rhamnose.
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2mM DTT and 30% (w/v) glycerol. Before use, the enzyme was
extensively dialysed against a 10mM sodium phosphate buffer
pH 7.0.
Other methods
The protein concentration was determined by the Coomassie blue
staining method19, using BSA as a standard protein. Statistical
analysis was performed using the two-way ANOVA test carried out
with Graphpad 6.0 software. IC50 determination was performed
using standard statistical software (GraphPad Instat version 6.0,
San Diego, CA). Results are reported as the mean of the values
and the 95% confidence interval from at least three independent
measurements.
Results and discussion
We recently reported that components of a methanolic extract of
Zolfino bean, eluting as the most hydrophobic fractions from an
HPLC reverse phase column, act as a promising source of ARDIs16.
Thus in the present work, a methanolic extract enriched in these
components was fractionated by reverse phase HPLC (see
Methods), and the relative elution profile and the differential
inhibitory activity of the eluted fractions (F1–18) are reported in
Figure 1(A,B), respectively.
Components eluting with tR from 24 to 26min (Figure 1, F13),
which also showed the highest effectiveness as ARIs and the most
appreciable differential inhibitory action, were further investigated.
The inset of Figure 1 reports the inhibitory action on both L-idose
and HNE reduction versus the amount of F13 (expressed as
absorbance units at 254 nm/ml assay). The differential inhibitory
activity of the sample with respect to the reduction of the two
substrates with an IC50 for HNE (0.069 AU254 nm/ml assay, with
0.059–0.080, 95% confidence limits) was clear, and was approxi-
mately two fold higher (p< 0.05) than that measured for L-idose
(IC50¼0.029 AU254 nm/ml assay, with 0.023–0.036, 95% confi-
dence limits).
A further HPLC fractionation of F13 (see Methods) separated
the suitable sub-fractions for the evaluation of the inhibitory cap-
acity and for component identification. Thus, fractions with tR
from 22 to 28min, namely 13a–13e (Figure 2, Panel A), were
manually collected, dried and analysed for differential inhibitory
ability (Figure 2, Panel B). As reported in Figure 2, the elution
components showed a different ability in differentially inhibiting
hAKR1B1. Fractions 13 b and 13d appeared to be the most power-
ful inhibitors, with a comparable effectiveness in inhibiting L-idose
reduction. However, when considering their differential inhibitory
ability (DI) between L-idose and HNE, despite comparable values
(16.78 ± 7.5% and 13.41 ± 6.4% for 13 b and 13d, respectively), stat-
istical significance (p values <0.05) was observed only for data
referring to 13 b. The remaining three fractions (namely 13a, 13c
and 13e) showed a lower inhibitory capacity and no significant
evidence of differential inhibition.
In order to reveal the chemical structures of their bioactive
components, sub-fractions 13a–e were analysed by means of
HPLC-PDA/UV-ESI-MS/MS techniques.
The results showed the presence of triterpenoid saponins (1–7)
in all the analysed fractions, whose peak distribution (identified
with the same corresponding numbers) is illustrated in Figure 3.
All compounds, except for compound 3, were identified by com-
paring their spectral data (UV and ESI-MS/MS) with those reported
in the literature20–22. In addition, compounds 1 and 2 were com-
pared with authentic pure standards. Thus, the structures were
assigned as follows: soyasaponin Ba (V), SSBa (1), soyasaponin
Bb (I), SSBb (2), soyasaponin Bd (sandosaponin A), SSBd (4),
soyasaponin ag, SS ag (5), 3-O-[R-L-rhamnopyranosyl(1 ! 2)-a-D-
glucopyranosyl(1! 2)-a-D-glucuronopyranosyl]olean-12-en-22-
oxo-3a,-24-diol (6), and soyasaponin bg, SS bg (7) (Figure 4). All
saponins identified had previously been isolated from Phaseolus
vulgaris20,23,24, whereas compound 3 remained unidentified.
The molecular weights of all the constituents were deduced
from the presence in the full mass spectra, acquired in the posi-
tive ion mode, of both protonated [MþH]þ and sodiated
[MþNa]þ ion molecular peaks. The analysis of the fragmentation
patterns led to the identification of all the molecules as soyasapo-
nins B and E, with two different aglycones (soyasapogenol B and
E) and two different trisaccharide sugar chains attached to the C-3
hydroxyl position of the aglycone moieties. Furthermore, saponins
5 and 7 showed the sugar 2,3-dihydro-2,5-dihydroxy-6-methyl-4H-
pyran-4-one (DDMP) attached to the C-22 hydroxyl group.
The ESI-MS/MS of sodium adduct ions (Table 1) of compound
1 ([MþNa]þ at m/z 981), compound 4 ([MþNa]þ at m/z 979),
and compound 5 ([MþNa]þat m/z 1107), showed very similar
fragmentation pathways, with diagnostic peaks at m/z 819, 657,
and 481 (compound 1), m/z 817, 655, and 479 (compound 4), and
m/z 945, 783, and 607 (compound 5) due to the sequential losses
of one glucose ([M 162þNa]þ]), one galactose
([M 162 162þNa]þ]), and one glucuronic acid
([M 162 162 176þNa]þ]) residues, respectively, thus confirm-
ing the presence of a trisaccharide chain linked to the aglycones.
According to common fragmentation patterns observed for sapo-
nins25, the MS/MS spectra also showed signals corresponding to a
Figure 6. Inhibition curves of hAKR1B1 by soyasaponins. Authentic standards of
SSBa (Panel A) and SSBb (Panel B) were used to evaluate the dose-dependent
inhibitory effect on 8mU of the enzyme acting either on 0.8mM of L-idose
(circles) or 0.04mM of HNE (triangles). Error bars (when not visible are within the
symbol size) represent the standard deviations of the mean from three to five
independent measurements. Asterisk(s) indicate significant differences between L-
idose and HNE (p 0.05, p 0.01, p 0.001).
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sodium-cationised sugar chain, such as the ion peaks at m/z 541
comprised of glucose, galactose, and glucuronic acid
([162þ 162þ 194þNa]þ), detected for the three compounds. In
addition, other fragments corresponding to the trisaccharide chain
sodium adduct ions were detected, due to the elimination of one
molecule of water [162þ 162þ 194 – 18þNa]þ, a carboxylic resi-
due [162þ 162þ 194 – 18 – 44þNa]þ, and the glucuronic acid
unit [162þ 180þNa]þ. Thus, compounds 1 and 4 were identified
as SSBa and SSBd, which differed in the aglycone moieties repre-
sented by the soyasapogenol B and soyasapogenol E, respectively.
Compared to 1, compound 5 showed in addition a residue of
126 amu corresponding to a DDMP unit, and thus was character-
ised as soyasaponin ag.
The full mass spectra of compounds 2, 6, and 7 showed
sodium adduct molecular ion peaks [MþNa]þ at m/z 965, 963,
and 1091, respectively.
Ion peaks corresponding to the subsequent losses of rhamnose
[M–146þNa]þ, glucose [M–146 162þNa]þ, and glucuronic acid
[M–146 162 176þNa]þ units can be observed in the fragmentation
patterns of all three precursor ions, indicating the presence of the same
trisaccharide chain in these three saponins. This evidence was confirmed
by the detection of fragments atm/z 507 ([146þ 162þ 194þNa]þ), 489
([146þ 162þ 194 – 18þNa]þ), 445 ([146þ 162þ 194 – 18 – 44
þNa]þ), 427 ([146þ 162þ 194 – 18 – 18  44þNa]þ), and 331
([146þ 180þNa]þ) related to the glycosidic portion.
The aglycones were established as soyasapogenol B for com-
pound 2 and soyasapogenol E for compound 6, as deduced from
the presence of product ion peaks at m/z 479 and 481, respect-
ively. Thus, compounds 2 and 6 were identified as SSSBb and
3-O-[R-L-rhamnopyranosyl(1!2)-a-D-glucopyranosyl(1!2)-a-D-glucur-
onopyranosyl]olean-12-en-22-oxo-3a,-24-diol, respectively. In addition,
compound 7 was characterised by the presence of a DDMP residue
and the same aglycone of 2, leading its structure being identified as
soyasaponin bg. As an example, the MS/MS spectra of compounds 1
and 6 are shown in Figure 5. Finally, compound 3, which was
detected in F13b coeluting with compound 2, showed a molecular
weight of 970 amu, as deduced from both the sodium adduct
[MþNa]þ and protonated [MþH]þ molecular ion peaks at m/z 993
and 971, respectively.
The analysis of the fragmentation pathway of m/z 993 precur-
sor ion suggested the presence of two hexose residues (peaks at
m/z at 831 [M 162þNa]þ and 669 [M 162 162þNa]þ) in the
saccharide chain. However, the detection of the peak at m/z 609
([M 162 162 60þNa]þ) suggested the presence of an acetyl
group. On the other hand, the base peak was represented by a
product ion at m/z 555, related to the oligosaccharide chain, thus
differing from both glycosidic portions linked to the other identi-
fied substances. Although the MS/MS analyses clearly indicated
that compound 3 was a triterpenoid saponin related to the other
analysed molecules, the complete assignment of its structure was
Figure 7. Kinetic characterisation of SSBa as hAKR1B1 inhibitor. Panel A and Panel C are the Hanes–Woolf plots obtained when the activity of the purified enzyme
(8mU) was measured at the indicated concentrations of the substrate, in the absence () or in the presence of the following inhibitor concentrations: () 9mM, (~)
18.5mM, () 37.1mM, () 59.4mM. Panel B and Panel D refer to the secondary plots of the slopes (1/appVmax) and the ordinate intercept (appKm/appVmax) of the relative
Hanes–Woolf plot, as a function of the inhibitor concentration. Panel A and Panel B refer to L-idose; Panel C and Panel D refer to HNE. Error bars (when not visible are
within the symbols size) represent the standard deviations of the mean from at least three independent measurements.
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not possible on the basis of the MS data. Thus, compound 3
remained unidentified.
As highlighted by the LC-MS analyses (Figure 3), the investi-
gated fractions (F13a–F13e) were a mixture of two or more com-
pounds. Referring to the inhibition data (Figure 2), the most
interesting fraction of the Zolfino extract was F13b in which the
MS analysis revealed, besides SSBa and SSBb, the presence of
SSBd (also present in F13c) and, only for this fraction, of a yet
unidentified saponin (peak 3 in Figure 3) with a molecular mass
of 970 amu. This made it difficult to unequivocally associate the
specific saponin species with their differential inhibitory features.
Nevertheless an association was attempted. Compound 1, whose
presence was revealed in both F13a and F13b, and compound 2,
which was detected from fraction F13a to F13e, did not seem to
exert any differential inhibitory action. This was evident from look-
ing at the inhibition data of F13a in which these two compounds
predominate. Similarly, the fact that fractions 13c, 13d and 13e,
did not exhibit a significant differential inhibition, led the initial
conclusion that also compounds 5–7 appeared to be devoid of a
differential inhibitory capacity. This left the unidentified com-
pound 3 and possibly compound 4 (SSBd) as the only potential
ARDIs conferring differential inhibition to F13b.
Such a conclusion, however, is debateable. In fact, the simul-
taneous presence in a mixture of more than one component
capable of inhibiting the enzyme, may mask the possible presence
of an ARDI. In this regard, the couple of compounds 1 and 2 is
indicative of the difficulty in searching for differential inhibitors in
multi-component mixtures. In this case, the availability of authen-
tic standards of compounds 1 and 2 identified in the Zolfino bean
(SSBa and SSBb, respectively) facilitated a detailed kinetic investi-
gation in order to gain insights into the inhibitory features of
these two unresolved components present in F13a.
To compare inhibition curves of different substrates, the sub-
strates concentration must be kept at values equal or equally pro-
portional to their respective KM values. This to allow the enzyme
to act on each substrate in comparable conditions. In the present
study the concentrations of the two used substrates were chosen
being close to their KM values, i.e. 0.04mM for HNE17 and 0.8mM
for L-idose18. The results reported in Figure 6 indicated that SSBa
behaved like an ARI since it was able to inhibit L-idose and HNE
reaction with essentially the same effectiveness, with an IC50 of
40 mM (34–47mM, 95% confidence limits) and 47mM (37–59 mM,
95% confidence limits), respectively. Conversely, SSBb, although
less efficient than SSBa as an inhibitor, showed a differential
inhibitory action between L-idose and HNE, since the IC50 for HNE
reduction (360 mM; 290–440mM 95% confidence limits) was two
fold higher than that for L-idose reduction (IC50 170 mM;
130–220 mM, 95% confidential limit).
Figure 8. Kinetic characterisation of SSBb as hAKR1B1 inhibitor. Panel A and Panel C are the Hanes–Woolf plots obtained when the activity of the purified enzyme
(8mU) was measured at the indicated concentrations of the substrate, in the absence () or in the presence of the following inhibitor concentrations: () 17.8mM,
(~) 35.5mM, () 89mM. Panel B and Panel D refer to the secondary plots of the slopes (1/appVmax) and the ordinate intercept (appKM/appVmax) of the relative
Hanes–Woolf plot, as a function of the inhibitor concentration. Panel A and Panel B refer to L-idose; Panel C and Panel D refer to HNE. Error bars (when not visible are
within the symbols size) represent the standard deviations of the mean from at least three independent measurements.
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Figures 7 and 8 report a graphical analysis performed by the
Hanes-Woolf plot of the kinetic data for the two inhibitors SSBa
and SSBb, respectively. Table 2 reports the ternary enzyme-sub-
strate-inhibitor complex dissociation constant (K’i) and the binary
enzyme-inhibitor complex dissociation constant (Ki) values. SSBa,
acting as a mixed inhibitor, is characterised by rather low values
of Ki and K’i which are essentially identical for both substrates,
thus justifying its higher efficiency as an ARI with respect to SSBb
and, at the same time, its failure to exert any differential inhibitory
action (Figure 6, Panel A). Conversely, SSBb acts on the two sub-
strates by exhibiting a different inhibition model, behaving essen-
tially as a purely non-competitive inhibitor with respect to L-idose,
and displaying an uncompetitive mode of action with respect
to HNE.
These results, which exemplify the predictable masking effect
of an ARI over an ARDI, clearly indicate that either the isolation of
single components or the availability of authentic standards are
necessary to ascertain the ARDI features of molecule mixtures. In
addition, these results enable SSBb to be included as a potential
contributor to the differential inhibitory action of fraction 13 b.
Unfortunately, the commercial SSBd standard (compound 4) that
we used to verify the possible contribution of this molecule to the
differential inhibitory action of F13b, was revealed to be, in our
hand, unsuitable. In fact, unlike other commercially available
standard saponins used in the experimentation (i.e. SSBa and
SSBb), the SSBd MS analysis failed to reveal either the expected
compound or signs of possible saponin degradation products.
A final consideration emerging from the kinetic characterisation
of SSBa and SSBb, is that although the most favourable and obvi-
ous feature for a molecule to behave as an ARDI towards two dif-
ferent substrates undergoing transformation would be the ability
to express the inhibitory action only on one of them, different
models of action of the inhibitor towards the two different sub-
strates may also generate conditions for an inhibitory differential
action. In fact, depending on the concentration values of the sub-
strates in the assay, the enzyme may be more or less susceptible
to inhibition depending on the inhibitory mechanism of action. A
computer assisted simulation of the enzyme inhibition determined
by different inhibitory mechanisms was thus performed at differ-
ent substrate concentrations. The general equation (Equation (1))
was exploited, which was derived in ES steady state conditions for
a general mixed type of non-competitive inhibition26, in which,
besides the above defined Ki and K 'i classical enzyme kinetic sym-
bols are adopted:
v0 ¼ kcat ET½ 
,
1þ KM
S½  þ
KM I½ 
Ki S½ 
þ I½ 
K 'i
 !
(1)
This enabled the residual activity versus the inhibitor concen-
tration curves to be generated at substrate concentrations ranging
from 1/10 KM to 10 KM. The inhibition mechanism types, defined
on the basis of the relative values of the dissociation constants,
were: competitive (K’i/Ki¼ 102), uncompetitive (K’i/Ki¼102), and
purely non-competitive (K’i/Ki¼1) (Figure 9, Panels A–C).
In the present case (Table 2), the K’i value for HNE reduction
for SSBb is comparable to the constant referred to L-idose.
However, the different mode of action towards the two different
Table 1. ESI-MS/MS and chromatographic data (retention time, tR) of triterpenoid saponins 1–7 detected in the fractions 13 a–e from Phaseolus vulgaris.
Peaka Saponins tR (min) [MþH]þ (m/z)
[MþNa]þ
(m/z) MS/MS ions (m/z)b/ Assignments
1 Soyasaponin Ba (V) 25.3 959 981 819/[MGlcþNa]þ 657/[MGlcGalþNa]þ 481/
[MGlcGalGluþNa]þ 541/[GlcþGalþGluþNa]þ 523/
[GlcþGalþGlu–H2OþNa]þ 505/[GlcþGalþGlu–2H2OþNa]þ 461/
[GlcþGalþGlu–2H2O-CO2þNa]þ 443/[GlcþGalþGlu–3H2O-CO2þNa]þ
347/[GlcþGal–H2OþNa]þ
2 Soyasaponin Bb (I) 26.0 943 965 819/[M RhaþNa]þ 657/[M RhaGlcþNa]þ 481/
[M RhaGlcGluþNa]þ 525/[RhaþGlcþGluþNa]þ 507/
[RhaþGlcþGlu–H2OþNa]þ 489/[RhaþGlcþGlu–2H2OþNa]þ 445/
[RhaþGlcþGlu–2H2O-CO2þNa]þ 427/[RhaþGlcþGlu–3H2O-
CO2þNa]þ 331/[RhaþGlc–H2OþNa]þ
3 Unidentified 25.8 971 993 831/[MHexþNa]þ 669/[M 2HexþNa]þ 555/[Saccharide chainþNa]þ
4 Soyasaponin Bd
(sandosaponin A)
26.5 957 979 817/[MGlcþNa]þ 655/[MGlcGalþNa]þ 479/
[MGlcGalGluþNa]þ 541/[GlcþGalþGluþNa]þ 523/
[GlcþGalþGlu–H2OþNa]þ 505/[GlcþGalþGlu–2H2OþNa]þ 461/
[GlcþGalþGlu–2H2O-CO2þNa]þ 443/[GlcþGalþGlu–3H2O-CO2þNa]þ
347/[GlcþGal–H2OþNa]þ
5 Soyasaponin ag 26.8 1085 1107 945/[MGlcþNa]þ 783/[MGlcGalþNa]þ 607/
[MGlcGalGluþNa]þ 523/[GlcþGalþGlu–H2OþNa]þ 505/
[GlcþGalþGlu–2H2OþNa]þ 461/[GlcþGalþGlu–2H2O-CO2þNa]þ
443/[GlcþGalþGlu–3H2O-CO2þNa]þ 347/[GlcþGal–H2OþNa]þ
6 3-O-[R-L-rhamnopyranosyl(1!2)-
a-D-glucopyranosyl(1!2)-a-D-
glucuronopyranosyl]
olean-12-en-22-oxo-3a,-24-diol.
26.3 941 963 817/[M RhaþNa]þ 655/[M RhaGlcþNa]þ 479/
[M RhaGlcGluþNa]þ 525/[RhaþGlcþGluþNa]þ 507/
[RhaþGlcþGlu–H2OþNa]þ 489/[RhaþGlcþGlu–2H2OþNa]þ 445/
[RhaþGlcþGlu–2H2O-CO2þNa]þ 427/[RhaþGlcþGlu–3H2O-
CO2þNa]þ 331/[RhaþGlc–H2OþNa]þ
7 Soyasaponin bg 26.7 1069 1091 945/[M RhaþNa]þ 783/[M RhaGlcþNa]þ 607/
[M RhaGlcGluþNa]þ 525/[RhaþGlcþGluþNa]þ 507/
[RhaþGlcþGlu–H2OþNa]þ 489/[RhaþGlcþGlu–2H2OþNa]þ 445/
[RhaþGlcþGlu–2H2O-CO2þNa]þ 427/[RhaþGlcþGlu–3H2O-
CO2þNa]þ 331/ [RhaþGlc–H2OþNa]þ
aCompound numbers correspond with peak numbers in Figure 3. bMS/MS data are obtained from the fragmentation of the [MþNa]þ precursor ions. Gal: galactose;
Glc: glucose; Glu: glucuronic acid; Hex: hexose; Rha: rhamnose.
Table 2. Inhibition constants (mM) for SSBa and SSBb inhibiting either L-idose or
HNE reduction. The value constants for SSBa and SSBb come from the steady
state kinetic analysis described in Figures 7 and 8, respectively.
SSBa SSBb
Substrate K’i (mM) Ki (mM) K’i (mM) Ki (mM)
L-idose 24 ± 2 66 ± 17 191 ± 11 176 ± 35
HNE 23 ± 4 65 ± 12 248 ± 19 n.a.
Data are reported as the mean ± SEM; n.a.: not applicable.
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substrates shown by this inhibitor may generate a differential
inhibitory action (Figure 9, Panel D). This result explains the
observed differential inhibitory action in conditions, such as those
adopted in Figure 6, that mimic the hyperglycaemia and oxidative
stress, with the sugar levels in the mM range and HNE levels in
the mM range.
Conclusions
Following previous reports for Zolfino bean extracts that show its
potential to inhibit AKR1B127 and the recent observation for
Zolfino bean that it exhibits an AKR1B1 differential inhibitory
action16, the results emerging from the present work reveal the
ability of some saponins to differentially inhibit the human aldose
reductase enzyme. This was the case of SSBb and, possibly, of
SSBd and/or an as yet unidentified saponin (compound 3) present
in the most differentially active sample derived from the Zolfino
bean extract fractionation (Figure 2, Panel B, F13b).
The comparison between SSBb, acting as ARDI, and SSBa, act-
ing as ARI is interesting. In this case, while the aglycone scaffold,
which is common to both saponins, may represent the basic struc-
tural element of the interaction between the inhibitor and the
enzyme, the sugar moiety of these molecules may modulate the
differential inhibitory action.
Another aspect emerging from the present study is the possi-
bility to extend the concept of differential inhibition to situations
in which the inhibitor is active on different substrates, but
through a different inhibitory model. In such a case, combined
values of the concentration of the different substrates may gener-
ate differential inhibition.
It is clear that it is difficult to identify ARDIs in mixtures in
which conventional ARIs are also present. In fact, the differential
activity of an ARDI can easily be masked by the inhibitory action
of the co-occurring ARIs, as is the case with SSBb and SSBa
(Figure 6, F13a). This implies that for the search for new ARDIs to
be successful, even modest indications of differential activity need
to be considered while looking at any possible improvement in
the mixture components separation.
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